HKDC1 and neoplasm: As a result, HKDC1 inhibition and low dose PD-1 antibodies (αPD-1low, 25 μg/mouse) each modestly inhibited tumor growth, while siHKDC1 further enhanced the antitumor effects of αPD-1 (Fig. 5a).